

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Global Cannabis Applications Corp.** (the "Issuer")

Trading Symbol: **APP**

Number of Outstanding Listed Securities: **184,837,473 (as at February 28, 2021)**

Date: **March 4, 2021**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer is a global leader in designing, developing, SaaS licensing and acquiring innovative data technologies for the medical cannabis industry. Its Citizen Green and Efixii platforms are the world's first end-to-end - from patient to regulator - medical cannabis data solutions. They use six core technologies: mobile applications, artificial intelligence, RegTech, smart databases, Ethereum blockchain and GCAC smart rewards. These technologies transparently disclose cannabis chain-of-custody events, thereby enabling patients to provide crowd-sourced medical cannabis efficacy data. Driven by digital and cannabis industry experts, the Issuer is focused on generating revenue from SaaS licensing its technology and acquiring high quality cannabis datasets that improve patient outcomes and to become the world's largest cannabis efficacy data provider.

During the month of February 2021, the Issuer actively continued general and corporate operations with no changes to material activities.

Global Outbreak of COVID-19 Disclosure: The actual and threatened spread of the virus globally has had a material adverse effect on the regional economies in which the Issuer operates and could continue to result in negative impacts on the stock market, including trading prices of the Issuer's shares and the ability to raise capital, and could impact the Issuer's operations.

2. Provide a general overview and discussion of the activities of management.

During the month of February 2021, management continued to support and control the Issuer's business activities and develop the Issuer's business with a focus on creating broader awareness of the Issuer and continued development of product line.

On February 3, 2021, the Issuer announced by way of news release that it has closed its first tranche of a non-brokered private placement (the "Private Placement").

Pursuant to the Private Placement, the Issuer has issued 3,288,561 units at a price of \$0.105 per unit (the "Financing Units") for gross proceeds of \$345,299 and 1,360,000 units at a deemed price of \$0.105 per unit (the "Settlement Units") to settle an aggregate of \$142,800 in debt to various creditors of the Issuer. Each Financing Unit and Settlement Unit consists of one common share and one common share purchase warrant (a "Warrant"), whereby each Warrant entitles the holder to purchase one additional common share of the Issuer for a period of three years from closing at an exercise price of \$0.17 per common share.

In connection with the Private Placement, the Issuer issued 223,919 finders' units. Each finders' unit consists of one common share and one common share purchase warrant having the same terms as the Warrants. Net proceeds from the Private Placement will be used for working capital and general corporate purposes. All securities issued in connection with the Private Placement are subject to a statutory hold period of four months from the date of issuance.

On February 4, 2021, the Issuer announced by way of news release that it has commenced the licensing process to become a Health Canada Medical Sales License holder under the Cannabis Act. The Issuer will operate as a non-possession cannabis retailer that connects buyers to cultivators via Health Canada practitioners using a retail dropship model.

The Issuer developed a new Cannabis-Consultation service for Efixii, where patients request an in-app consultation for medical cannabis with a registered Health Canada practitioner. Then, in accordance with the Cannabis Act, the practitioner prepares the patient's official Medical Document and sends to the Issuer's shop where the patient orders Efixii-certified medical cannabis.

The Issuer's recent funding of \$1,000,000 will be used to acquire a Medical Sales License and establish a retail dropship web shop. The Issuer's prior agreement with Purity-IQ means that the Efixii shop dropships trustworthy, certified medical cannabis, thereby ensuring better patient outcomes.

On February 22, 2021, the Issuer announced by way of news release that it has closed its second and final tranche of a non-brokered private placement (the "Private Placement").

Pursuant to the Private Placement, the Issuer has issued 6,184,490 units at a price of \$0.105 per unit (the "Financing Units") for gross proceeds of \$649,371.46 and 1,087,618 units at a deemed price of \$0.105 per unit (the "Settlement Units") to settle an aggregate of \$114,199.89 in debt to various creditors of the Issuer. Each Financing Unit and Settlement Unit consists of one common share and one common share purchase warrant (the "Warrants" and each a "Warrant"), whereby each Warrant entitles the holder to purchase one additional common share of the Issuer for a period of three years from closing at an exercise price of \$0.17 per common share.

In connection with the Private Placement, the Issuer paid finder's fees in the amount of \$23,885.16, issued 44,755 finders' units, and 227,192 finder's warrants with each finders' unit having the same terms as the Financing Units and each finder's warrant having the same terms as the Warrants. Net proceeds from the Private Placement will be used for working capital and general corporate purposes. All securities issued in connection with the Private Placement are subject to a statutory hold period of four months from the date of issuance.

Also on February 22, 2021, the Issuer announced by way of news release it has signed a Memorandum of Understanding ("Agreement") to supply Efixii QR Codes on the retail packaging of CBD Agrocasa ("Agrocasa"), Europe's largest CBD producer. The Agreement is for the Efixii QR Codes to be applied to an initial retail rollout of 400 liters of CBD oil tinctures, containing approximately 2 million grams of cannabis, at a SaaS license cost of CA\$0.20 per gram.

The Issuer's Efixii platform attests to a CBD products' lifecycle, from seed to sale, and is the only cannabis data platform in the world that then acquires actual user-efficacy data on CBD consumption using its Efixii app (now available on Apple's App Store and Google's Play Store).

Subject to a successful collection of efficacy data in the initial 400 liter run, both parties agree to work in good faith to expand the commercial use of Efixii across Agrocasa's harvests in the future.

The Issuer's cannabis data is the intellectual property ("IP") of GCAC. The IP creates an inherent difficulty in replicating, or directly competing with the Issuer's medical cannabis datasets. The Issuer defined their protocols in a provisional patent application, 'System of Process and Tracking Cannabis Products and Associated Method Using Blockchain' as filed with the U.S. Patent and Trademark Office on December 17, 2020.

The above noted news releases can be viewed under the Issuer's profile on SEDAR (www.sedar.com) and on the Issuer's Disclosure Page on the Canadian Securities Exchange's website.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None to report during the month of February 2021.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report during the month of February 2021.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer signed the Agreement to supply Efixii QR Codes on the retail packaging of Agrocasa, Europe's largest CBD producer.

The Issuer commenced the licensing process to become a Health Canada Medical Sales License holder under the Cannabis Act.

Please see Item #2 for further details

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report during the month of February 2021.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report during the month of February 2021.

8. Describe the acquisition of new customers or loss of customers.

The Issuer signed the Agreement to supply Efixii QR Codes on the retail packaging of Agrocasa, Europe's largest CBD producer.

Please see Item #2 for further details.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

The Issuer commenced the licensing process to become a Health Canada Medical Sales License holder under the Cannabis Act.

Please see Item #2 for further details.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None to report during the month of February 2021.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report during the month of February 2021.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report during the month of February 2021.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

On February 3, 2020, the Issuer issued 1,360,000 Settlement Units at a deemed value of \$0.105 per unit to satisfy an aggregate of \$142,800 in debt to various creditors of the Issuer.

On February 22, 2020, the Issuer issued 1,087,618 Settlement Units at deemed price of \$0.105 per unit to settle an aggregate of \$114,199.89 in debt to various creditors of the Issuer.

Please see Item #2 for further details.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Units ⁽²⁾	9,473,051	Private placement financing priced at \$0.105 per Unit	\$994,670.36; working capital
Units ⁽²⁾	2,447,618	Units issued to settle debt at a deemed value of \$0.105 per Unit	\$256,999.89 debt settled
Units ⁽²⁾	268,674	Finder's Units issued in connection with above referenced private placement financing	Not applicable
Warrants	227,192	Finder's Warrants issued in connection with above referenced private placement financing	Not applicable
Common Shares	2,962,726	Common shares issued in connection with exercise of warrants	\$185,286.30; working capital

(1) State aggregate proceeds and intended allocation of proceeds

(2) Each Unit consists of one common share and one common share purchase warrant exercisable into an additional common share at an exercise price of \$0.17 for a period of three years from the date of issuance.

15. Provide details of any loans to or by Related Persons.

None to report during the month of February 2021.

16. Provide details of any changes in directors, officers or committee members.

None to report during the month of February 2021.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Form 2A, Listing Statement, dated October 16, 2014, available on the Issuer's Disclosure Page on the Canadian Securities Exchange's website.

THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 4, 2021

Bradley Moore
Name of Director or Senior Officer

/s/ Bradley Moore
Signature

Chief Executive Officer
Official Capacity

<i>Issuer Details</i>	For Month End	Date of Report
Name of Issuer Global Cannabis Applications Corp.	February 2021	YYYY/MM/DD 2021/03/04
Issuer Address PO Box 43, Suite 830 1100 Melville Street Vancouver, BC V6E 4A6	Issuer Fax No. Not applicable	Issuer Telephone No. 1 (800) 409-5679
Contact Name Bradley Moore	Contact Position Chief Executive Officer	Contact Telephone No. (855) 269-9554
Contact Email Address info@cannappscorp.com	Web Site Address https://cannappscorp.com/	